Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
NBC’s Richard Engel has son diagnosed with Rett Syndrome. Engel and his wife were on the nightly news.
Earn money? BTX will:
Renevia(®) successfully met the primary endpoint in a European pivotal study
for the treatment of HIV-Associated Facial Lipoatrophy. Treated patients
retained approximately 100% of transplanted volume at 6 months and there were
no device related serious adverse events noted during the trial.
BioTime plans to submit the Renevia(®) application for CE Marking later this
quarter with an expected approval in the second half of 2018. As the company
has previously reported, BioTime views the European trial as a gateway into a
larger multibillion-dollar market opportunity, like cosmetic facial
aesthetics. Currently, the U.S. facial fat transfer and dermal facial filler
market is estimated to be over 4 billion dollars and growing at or near
double digits.
I am not sure. To the right on my screen is a rectangle that says “waiting”. I thought it wold be broadcast live and then available within 24 hours to review, but I may very well be wrong.
3 pm EST.
Anavex Life Sciences
Noble 14th Annual Insitutional Investor Conference
Today at 3pm, Anavex Life Sciences will webcast its Corporate Presentation
at Noble 14th Annual Institutional Conference.
I received the above message from Anavex
9:00am - PANEL PRESENTATION - Studio 1 - Central Nervous System: Is there a cure for Alzheimer’s on the Horizon?
Alzheimer’s Disease is the most common form of dementia (accounts for 60 to 80 percent of cases) and other cognitive abilities serious enough to interfere with daily life. Although a cure remains elusive, the moderator will guide a discussion around current technologies and encouraging new discoveries in the treatment of this and other neurodegenerative diseases. 50 minute presentation
Noble conference tomorrow.
Thank you for the link about precision medicine Davos panel discussion. It confirms what some of us have been saying about being patient and doing it right. I caught the part about focusing on the super responders because it fits with what Anavex is doing in its clinical trial.
It caught my attention too due to my own experience in a clinical trail. I developed cancer presumed to be caused by agent orange exposure from my Marine Corps service in Vietnam in the 1960s. I entered a gene therapy clinical trial in the late 1990s. Ever since then, I revisit the doctors that did that clinical trail. I noticed that they have always paid particular attention to me recalling a quite severe immune reaction I had to the treatment. At one point, I had chills, high fever, profuse sweating, and shook so much that I could hardly stay in the bed. My wife thought I was about to die, but I heard one of the doctors say “That’s good, that’s good. It’s working”, and apparently it did work as I am here today and in excellent shape overall. Today, they have modified the treatment I received and testing applying it to other types of cancer. The trial was interrupted due to one person dying in a another gene therapy trial around the same time I completed my trial. Gene therapy trials were suspended at that time, but fortunately are up and running today.
My speculation is that we made the low for 2018. The low of $2.65 for 2018, so far, is the lowest the AVXL share price has been since September of 2016 when it bottomed at $2.43 - $2.45 in September of 2016. However, despite what some on this board may dispute, the company has made progress since 2016. It certainly raised more funds and has uncovered more options for the potential uses and approval of AVXL 2-73. Although there has been a delay, it is likely to move forward with the 3 clinical trials at some point early this year. Furthermore, the indicators I have available to me, although not perfect, suggest that the selling/move down is exhausted for the time being. Therefore, my best guess, do your own DD, is that we are more likely due for a price move up in the near future. There is no point in Dr. M appearing at the Noble conference Monday, January 29, unless he has something to say. After all, the subject is whether there is a cure for AD on the horizon. I do not expect him to say anything definitive, but he certainly cannot say NO there is no hope for a cure or for treating AD because that has been the main focus of all of his efforts and endeavors over the past several years. Moreover, he has agreed to put himself in the position of having to say something about what the company is doing and will do in regard to its AD clinical trial. Let’s wait and see what he has to say next week.
Pogue: The problem I have expeienced in the past with some other emerging biotechs is that I lost my position. What I mean by that is you never know when a promising biotech may break out on very positive news and move dramatically (Of course, it works in the reverse if he news is very negative). Very positive news is usually FDA approval or news that makes it obvious there will be FDA approval, but it may be approval in Europe or elsewhere. Times are changing.
The mistake I have made in the past is to sell all of my position of an excellent biotech prospect only to see a dramatic move up aferwards. In other words, I lost my position at at crucial time. The moves upward (or downward) tend to be sudden, aburpt, and unexpected. Therefore, I, like many others on this board, am maintaining a core position in AVXL, and I buy and sell some shares as the share price cycles up and down. I try to buy trading shares well below my overall share price average, and I sell some or all of the trading shares above my share price average. I have owned AVXL stock for over 4 years, and there have been times I was down 35% or more. The stock has wide swings, but all emerging biotechs tend to be highly volitable. In any event, I now maintain a core position in promising biotech stocks like AVXL all the while trading some shares as well.
I do not want to become frustrated and lose my core position that I am holding for the long term; hopefully, for a dramatic move upwards at some point down the road. Frustration is an early stage of capitulation that may eventually cause you to give up at the wrong time.
I am not saying AVXL is a sure thing. It is not. No emerging biotech is. I have done and continue to do my DD, and I am holding the core position until I see the contrary handwriting on the wall if you know what I mean. Do your DD and decide for yourself if this is something you desire to own and maintain as a core position for as long it takes to either succeed or fail.
Good luck whatever you do.
I understand your frustration, but we do not know the reasons for the delay. Therefore, we should not make any assumptions. I cannot count the times I have heard the expression or explanation from persons I have been acquainted with that begin with "I assumed..." (only to be dead wrong). It may be that the many possible reasons for the delay are good or bad, but we simply do not know at this point. Of course, we will know sooner or later, but we should not assume that this news will be either x or y or negative or positive. We can only be sure about one thing - we do not know the reason or reasons for delay, but we do know a great deal about the scientific basis for AVXL - 273 and its possibilities if we have done our due diligence that has been published for everyone to see.
Your personal oppion is "not good" as to Missling's performance over the last 3 to 4 years years. To me that is purely an unsubstantiated, personal and meaningless opinion unless you have some special knowledge and expertise and you further delineate facts and examples to support how you arrived at this conclusion about Missling's performance over this 3 to 4 year period.
We may see a little weakness tomorrow; however, it appears that selling should be about exhausted for now although we need to see what tomorrow brings. If we get through tomorrow okay, the washout may be confirmed to be over with the share price likely to cycle upward. Let's face it though, we need some positive news for any big move to occur. Therefore, I am prepared to manage my expectations. I/we cannot make positive news happen. I am in this for the long term. At some point news will come. I will wait as long as it takes.
You cannot take the same actions as everyone else and expect to make money. You cannot expect that you will not feel discomfort. If you do invest in something that is widely accepted and comfortable to own, you cannot expect to acquire that investment at bargain prices. If you do invest here, you need to be willing and able to give yourself a chance to fail, but you may be investing at a time that provides a bargain price. However, you must be willing to be uncomfortable in owning it.
Yes, the drug is safe. The science seems definite about it acting on sodium and calcium channels, and it may also be an effective anti-amnesic, anti-depressant, and neuroprotective drug. Sigma-1 receptorsfunctionally downregulate certain proteins that play a major role in various pathophysiological conditions including depression, anxiety,epilepsy and brain injury following ischaemic stroke; it has been shown that activating the sigma-1 receptor with agonists can potentiallyreduce the impact of tau dysfunction....."
All of the above conditions may be related to the central nervous system. Blood pressure is related to the sympathetic nervous system, which is why one should check their blood pressure in the morning upon arising. Therefore, the criticism some have displayed about AVXL as if it is falsely touted as another "snake oil" is unjustified. Many diseases are related to the CNS.
Anavex has many options for obtaining FDA approval and foreign approval of AVXL 2-73 to treat various CNS and CNS related diseases. The odds of it gaining these approvals are increasing, but this is not yet reflected in the share price.
I like this from your post about new FDA rules: "Advance the use of new drug development tools and mobile technology for better capturing clinical trial data and the measurement of safety and benefit in pre- and post-market settings."
AVXL seems to be a candidate for conditional post-market approval. The technology exists to monitor it.
In the Just Paste it summary about AVXL someone posted the other day it said this: "....at higher doses, it acts as an antagonist on sodium and calcium channels. This mixed pharmacodynamic profilesuggests that ANAVEX 2-73 may also be an effective anti-amnesic, anti-depressant and neuroprotective drug [1] [2] [3] . Sigma-1 receptorsfunctionally downregulate certain proteins that play a major role in various pathophysiological conditions including depression, anxiety,epilepsy and brain injury following ischaemic stroke; it has been shown that activating the sigma-1 receptor with agonists can potentiallyreduce the impact of tau dysfunction....."
Funny, when I read that it acted on sodium and calcium channels I had the thought that AVXL may control blood pressure, which I think some postulate contributes to AD and cognitive decline. However, I am no expert either.
Reading the Bloomberg article Penny posted reminds me of peaks and valleys I experienced in my career where there have been times when everything seems to go wrong and times when everything seems to go right.
If you are involved in an attempt to achieve something big or a transformational goal as here where a small company seeks to develop the first effective treatment of Alzheimer’s and possibly other devastating CNS diseases, you must develop an attitude that you are willing to walk through the valley of death and fear no evil to obtain that goal. You have to have the courage, persistence and tenacity to get through the darkest of times, and you should always be thinking about what may go wrong when everything appears to be going great.
Anavex is attempting to do things that no one has ever done before. By its very nature, that’s far from easy to do. If it was easy, it would have already been done and done quickly. Don’t be deterred by it taking longer than many expect. Don’t be deterred by setbacks. Keep moving forward. That’s the only way to move or you will never succeed. Lastly, you should never fear that you may fail. If others think or say you have failed, ignore them. Get yourself up and going to try and try again. Do that and you might accomplish what has never been done before.
The plan is for owners of BTX to receive shares of Age X; however, I do not know of anything definitive about this spin off other than that the plans remain for a distribution of Age X shares to holders of BTX shares. This is supposed to happen in the near future.
In the meantime Age X and BTX are making advances in discovering important facts about genes that affect aging, regeneration, etc. Many are oblivious to what’s taking place. Apparently, Age X has made a discovery about the repression of COX7A1 in embryonic and cancer cells that is significant. Search COX7A1 on the internet to find out more about this. Also, search and find out about the Age X product Renelon, which may produce some short term income for Age X.
I am invested in BTX for the long term. I am not in it for the short term. I think this is an excellent long term investment, but I do not expect much of anything in the short term.I recommend you do your own due diligence, and that it should not be chosen to meet short term investment goals.
Thank you. Canada’s view of marijuana is sensible. Since you are in Canada, unfortunately your signature does not count. However, perhaps there are U.S. shareholders of InMed that may sign the petition assuming they are interested in expanding InMed’s potential marketing of its products in the U.S. I am a U.S. citizen that’s thankful to own InMed shares, and I believe that InMed’s development of drugs will benefit society.
Sign petition to reverse decades of failed policy re marijuana.
https://pac.petitions.moveon.org/sign/its-time-to-reverse-decades?source=mo&fb_test=0&akid=196502.35910586.mBm6Q7
No bid, ask prices published and no trades yet.
Sign petition to reverse decades of failed policy re marijuana.
https://pac.petitions.moveon.org/sign/its-time-to-reverse-decades?source=mo&fb_test=0&akid=196502.35910586.mBm6Q7
Sign petition to reverse decades of failed policy re marijuana.
https://pac.petitions.moveon.org/sign/its-time-to-reverse-decades?source=mo&fb_test=0&akid=196502.35910586.mBm6Q7
Sign petition to reverse decades of failed policy re marijuana.
https://pac.petitions.moveon.org/sign/its-time-to-reverse-decades?source=mo&fb_test=0&akid=196502.35910586.mBm6Q7
Fool me once shame on you, fool me twice shame on me.
One of possibly several problems for Intel is that Intel has known about its problem for sometime and planned on not disclosing the problem until later according to Reuters. Another problem is that the so-called patches may slow down Intel chips. See UPDATE 6-Security flaws put virtually all phones, computers at risk that says in Part:
''Speaking on CNBC, Intel's Krzanich said Google researchers
told Intel of the flaws "a while ago" and that Intel had been
testing fixes that device makers who use its chips will push out
next week. Before the problems became public, Google on its blog said Intel and others planned to disclose the issues on Jan. 9.
The flaws were first reported by tech publication The
Register. It also reported that the updates to fix the problems
could causes Intel chips to operate 5 percent to 30 percent more
slowly. (http://bit.ly/2CsRxkj) ''
InMed is looking to cannabinoids that could accomplish analogous disease-fighting outcomes without any dangerous physical addiction like opiates. It is highly likely there will be a switch in the future to cannabinoid pain relievers from the use of opioid pain reliever such as oxycodone and hydrocodone that have been accompanied by an increased rate of opioid abuse and addiction. The medical pain market is huge.
In the past, I have made numerous FOIA requests for information. Generally, the FDA has 20 days to respond. However, my experience was the FDA never responded in 20 days, and it seemed to take forever for them to respond. I received letters within 20 days, but the letters merely said they received the request and are working on it. It always took forever to get any further response, and usually the response was pretty much non responsive.
I have followed drug approvals, but I have also dealt with the FDA regarding Citizen Petitions, Orange Book listings, and other matters. I find that the FDA is similar to other bureaucracies and slower than one might expect.
However, in all fairness to the FDA, they are often over burdened. It is likely the FDA is processing a heavy load with every clinical trial participant seeking to expedite clinical with less expense under the new procedures. The FDA Chief is new and they are dealing with new procedures. The government beauracy is not accustomed to moving fast and adjusting to anything that's new.
I think that approving the AD and Rett trials is more complicated and with more variables than many people on this board comprehend and, again, I am sure that the FDA is receiving many more filings with companies seeking newer, faster,and cheaper approvals.
Missling may have misjudged the timing, but I for one do not condemn him for that. I have no reason to doubt his honesty.
It certainly is in Missling's interest that the AVXL 2-73 clinical trials succeed. People complain about the stock he has received as an incentive, but his stock too will be worthless if no clinical trial succeeds.
Additionally, besides the FDA, I have dealt with a lot of state and federal agencies over the years. I cannot think of one agency that has been prompt, and generally I found that they cannot even be relied upon to respond within their professed timelines.
Therefore, because my experience is that stuff happens and delays are common, my expectations are much lower than many on this board.
Based on the large academic and scientific support for Anavex's drug potential therapy for CNS diseases, I believe the odds of an approval of AVXL 2-73 for the treatment of some CNS disease is relatively high. Once it is approved for the treatment of any CNS disease, it will be prescribed off label for other CNS diseases. Anavex's pursuit of the orphan drug process is smart. Anavex needs to take its time and put forth the best efforts for a successful Rett trial. Not starting the Rett trial on time is not important to me. Taking the time to make sure that it has the best chance of success is important to me and should be for everyone that has an interest in Anavex for whatever reason. We do not know the reasons for the delay, but I believe everyone involved in the Rett trial feels the same that delays are not significant -- success is!
Except for AVXL and some other small cap stocks, the market is overvalued and overbought, and 2018's lower tax rates will provide the opportunity to take some profits in stocks that have had quite a run. A correction is likely to begin next week. Beginning in January 2018, we may see rotation to small cap stocks occur. AVXL may not participate immediately, but I am betting that it eventually will participate in the rotation to small cap stocks and momentum may be added as AVXL trials proceed. I see no valid reason to believe that trials will not eventually proceed. I am accustomed to delays, and I do not know of any good reason to be suspicious of the trial delays that have occurred. Frankly, I expected there would be trial delays based on my experiences in dealing with government agencies, including the FDA.
Ok, I am getting ready to buy more.
The market is overvalued and overbought, and 2018's lower tax rates will provide the opportunity to take some profits. A correction is likely to begin next week.
The market is overvalued and overbought, and 2018's lower tax rates will provide the opportunity to take some profits. A correction is likely to begin next week.
The market is overvalued and overbought, and 2018's lower tax rates will provide the opportunity to take some profits. A correction is likely to begin next week.
The market is overvalued and overbought, and 2018's lower tax rates will provide the opportunity to take some profits. A correction is likely to begin next week.
For richer or poorer until trial failure shall we part, I added shares today.
Inflammation. It’s good to see scientists coming around to targeting inflammation re: Alzheimer’s. Anavex has been speaking about inflammation and oxidative stress for quite sometime. See for example:
“Both data sets described that Aß1-42 (amyloid beta) significantly impairs biological function in the respective animal models and the observed regain of function confirmed the protective potential of ANAVEX sigma-1 receptor agonists against amyloid beta -induced toxicity. The former presentation further reported that although that the transgenic McGill rats had a very late stage of Alzheimer’s disease-like pathology (13 months of age), treatment with ANAVEX 3-71 fully reversed cognitive deficits, reduced amyloid pathology and also significantly reduced inflammation. Furthermore, the sustained recovery in cognition and pathophysiology observed following a month-long washout phase in advanced pathology (19 months of age) strongly suggests true disease-modifying properties of ANAVEX 3-71.”
See. Anavex Life Sciences Reports New Mechanism of Action Data Related to ANAVEX Compounds Targeting Sigma-1 Receptor. http://www.anavex.com/anavex-life-sciences-reports-new-mechanism-action-data-related-anavex-compounds-targeting-sigma-1-receptor/
“McGill University’s Hélène Hall, PhD, delivered the first poster presentation, “Targeting M1 muscarinic and sigma-1 receptors in Alzheimer’s disease: Reversal of pathological hallmarks and associated cognitive dysfunction in McGill-R-Thy1-APP rats.” This study showed that, using transgenic mice with Alzheimer’s-like amyloid pathology, compound Anavex 3-71 (five months of daily treatment), reduced inflammatory response in the brain and increased synaptogenesis. Furthermore, the compound decreased amyloid pathology and fully reversed Alzheimer’s-related cognitive deficits.”
“Besides the well-known accumulation of amyloid beta peptide and the formation of senile plaques, researchers have extensively described the brain inflammation and reduced synaptogenesis (the formation of new synapses between neurons) in Alzheimer’s.”
See Compounds that Target Sigma-1 Receptor Offer Promise in Battling Alzheimer’s, Says Anavex. https://alzheimersnewstoday.com/2017/04/06/anavex-sigma-1-receptor-agonists-ad-therapy/
Accumulation! Excellent! Positive!
Nidan: The article you reference is a must read for other posters that are doubtful or negative about the PD trial in Europe. However, it is clear that the highly competent experts involved with the research and studies are in Europe. Moreover, this European research was funded with the help of the Michael J. Fox Foundation! Therefore, naysayers I suppose need to condemn the Michael J. Fox Foundation as well as Anavex for continuing the research and studies, including the clinical trial in humans, in Europe. Additionally, it is obvious that the European researchers are connected with EU universities, which means these institutions support this important research as they have for several years that I have owned Anavex stock. Based on my DD and longstanding knowledge, I am at a loss in understanding how a number of posters have been so negative about the PD clinical trial taking place where all of the significant research on AVXL-273/PD has been conducted. Note too, that these European researchers have been presenters at a number of scientific PD conferences in the U.S. and Europe.
Exactly, I see no reason to be negative about the EU trial. I do see several reasons to be positive about this decision, and you point out some of those reasons.